{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T13:46:07Z","timestamp":1705585567750},"reference-count":11,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T00:00:00Z","timestamp":1394064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2014,5]]},"abstract":"Abstract<\/jats:title>Partially empty sella with growth hormone (GH<\/jats:styled-content>) deficiency is rarely reported in association with PHACE<\/jats:styled-content> (posterior fossa anomalies, cervicofacial infantile hemangiomas [IH<\/jats:styled-content>s], arterial anomalies, cardiac defects, eye anomalies, and midline\/ventral defects). Consequently, little is known about the effect of GH<\/jats:styled-content> replacement on the proliferation and involution of IH<\/jats:styled-content>s in children with PHACE<\/jats:styled-content>. We describe two children with PHACE<\/jats:styled-content> and partially empty sella, both of whom received GH<\/jats:styled-content> replacement for treatment of hypopituitarism. In our first patient we observed erythema and prominence of the vasculature in the hemangioma shortly after initiation of therapy at age 20\u00a0months, although after 4\u00a0weeks of treatment the appearance of the hemangioma stabilized and little change was seen during eight additional years of therapy. In our second patient we noted enlargement of the hemangioma after starting low\u2010dose GH<\/jats:styled-content> at age 5\u00a0years, prompting discontinuation of GH<\/jats:styled-content> replacement after 3\u00a0months of therapy. The hemangiomas continued to grow after discontinuation of GH<\/jats:styled-content> treatment. GH<\/jats:styled-content> administration in our patients was associated with erythema and prominence of IH<\/jats:styled-content>s. Our findings suggest that GH<\/jats:styled-content> replacement therapy may promote transient or more prolonged proliferation of IH<\/jats:styled-content>s and should be administered with close clinical monitoring.<\/jats:p>","DOI":"10.1111\/pde.12306","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T11:09:20Z","timestamp":1394104160000},"page":"337-340","source":"Crossref","is-referenced-by-count":9,"title":["Growth Hormone Replacement in Patients with PHACE Association and Hypopituitarism"],"prefix":"10.1111","volume":"31","author":[{"given":"Lily C.","family":"Uihlein","sequence":"first","affiliation":[{"name":"Dermatology Program Boston Children's Hospital Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Garzon","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Columbia University New York New York"},{"name":"Department ofPediatrics Columbia University New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Endocrinology Program Boston Children's Hospital Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn G.","family":"Liang","sequence":"additional","affiliation":[{"name":"Dermatology Program Boston Children's Hospital Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,6]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-0082"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2006.00287.x"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2007.01.017"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02338.x"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.107.485185"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.03135.x"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.1911029.x"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5319.1706"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb26221.x"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e31824ec3fb"},{"key":"e_1_2_4_12_1","first-page":"4201","article-title":"Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation","volume":"27","author":"Lincoln DT","year":"2007","journal-title":"Anticancer Res"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.12306","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.12306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T19:31:23Z","timestamp":1696015883000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.12306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,6]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1111\/pde.12306"],"URL":"https:\/\/doi.org\/10.1111\/pde.12306","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,6]]}}}